Does TYK2/JAK1 Show Potential in Inflammatory Diseases? - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Does TYK2/JAK1 Show Potential in Inflammatory Diseases?

Investigational inhibitor was not associated with treatment-related serious adverse events and produced biomarker changes consistent with pathway inhibition in healthy volunteers.

  • By

  • Andrea Surnit

  • July 6, 2026

  • 3 min

Share

Clinical Scorecard: Does TYK2/JAK1 Show Potential in Inflammatory Diseases?

At a Glance

CategoryDetail
ConditionInflammatory Diseases
Key MechanismsInhibition of TYK2 and JAK1 pathways
Target PopulationHealthy participants
Care SettingPhase 1 clinical trial

Key Highlights

  • SDC-1801 was well tolerated with mild to moderate adverse events.
  • Evidence of pharmacologic activity with reductions in IP-10 and high-sensitivity C-reactive protein.
  • Peak plasma concentrations observed 3 to 5 hours post-administration.
  • Food intake modestly increased drug exposure.
  • Limited renal elimination with less than 4% recovered unchanged in urine.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

        • One participant experienced treatment-related rhabdomyolysis.

        Patient & Prescribing Data

        Healthy participants in a clinical trial

        Potential for once- or twice-daily dosing based on pharmacokinetic data.

        Clinical Best Practices

        • Monitor for mild to moderate adverse events during treatment.
        • Consider food effects on drug absorption when prescribing.

        Related Resources & Content

        Original Source(s)

        Does TYK2/JAK1 Show Potential in Inflammatory Diseases?

        • by Andrea Surnit

        • July 6, 2026

        Related Content

        Lasers trigger pigmentation from past gold therapy

        Short-pulse lasers triggered chrysiasis more than 30 years after treatment in 2 patients with rheumatoid arthritis.

        Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial

        Can an antibody aid neuropsychiatric SLE diagnosis?

        Investigators compared a candidate biomarker across three diagnostic groups.